A detailed history of California State Teachers Retirement System transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, California State Teachers Retirement System holds 3,610 shares of ALDX stock, worth $17,291. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,610
Previous 3,610 -0.0%
Holding current value
$17,291
Previous $11,000 72.73%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$3.25 - $4.72 $3,484 - $5,059
-1,072 Reduced 22.9%
3,610 $11,000
Q1 2024

May 15, 2024

SELL
$2.77 - $4.22 $8,265 - $12,592
-2,984 Reduced 38.93%
4,682 $15,000
Q4 2023

Feb 13, 2024

SELL
$1.47 - $6.06 $64,725 - $266,827
-44,031 Reduced 85.17%
7,666 $26,000
Q3 2023

Nov 14, 2023

SELL
$6.11 - $8.16 $30,641 - $40,922
-5,015 Reduced 8.84%
51,697 $345,000
Q2 2023

Aug 21, 2023

BUY
$7.11 - $11.89 $403,222 - $674,305
56,712 New
56,712 $475,000
Q2 2022

Aug 15, 2022

SELL
$2.43 - $4.85 $50,923 - $101,636
-20,956 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$3.25 - $5.17 $17,052 - $27,126
-5,247 Reduced 20.02%
20,956 $93,000
Q3 2021

Nov 15, 2021

SELL
$7.94 - $11.31 $323,610 - $460,961
-40,757 Reduced 60.87%
26,203 $230,000
Q2 2021

Aug 16, 2021

BUY
$10.44 - $14.85 $699,062 - $994,356
66,960 New
66,960 $759,000
Q2 2020

Aug 17, 2020

SELL
$1.97 - $5.05 $69,210 - $177,416
-35,132 Closed
0 $0
Q1 2020

May 13, 2020

BUY
$1.62 - $6.4 $660 - $2,611
408 Added 1.17%
35,132 $87,000
Q2 2019

Aug 14, 2019

BUY
$6.0 - $9.0 $9,936 - $14,904
1,656 Added 5.01%
34,724 $208,000
Q4 2018

Feb 13, 2019

BUY
$7.26 - $13.29 $63,154 - $115,609
8,699 Added 35.7%
33,068 $274,000
Q2 2018

Aug 14, 2018

BUY
$6.95 - $9.18 $169,364 - $223,707
24,369 New
24,369 $194,000

Others Institutions Holding ALDX

About Aldeyra Therapeutics, Inc.


  • Ticker ALDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,323,100
  • Market Cap $279M
  • Description
  • Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...
More about ALDX
Track This Portfolio

Track California State Teachers Retirement System Portfolio

Follow California State Teachers Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of California State Teachers Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California State Teachers Retirement System with notifications on news.